May: Pulp shipments -1.7% y-o-y

More value than momentum, except for wood

Q2 preview

AUM rebound drives earnings growth

Norway: Best ideas Q2'25

Apr: Pulp shipments +2% y-o-y

Large forest deal at EV/EBITDA 36-60x

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

Mar: Pulp shipments +7% y-o-y

Hexagon AB: 2 directors

Two Directors at Hexagon AB bought/maiden bought 14,000 shares at between 93.510SEK and 94.100SEK. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...

ROE held back by too-high capital base

Storebrand (Buy, TP: NOK149.00) - Insurance repricing on track

Q1 PTP before amortisation was NOK1,167m, up 8% YOY, driven by strong growth in Banking and Insurance. While high sales activity had a negative impact on the insurance cost ratio, the combined ratio continued to improve through premium growth of 20% YOY, leaving Storebrand close to the 90–92% target for 2025. We have made fairly limited EPS revisions for 2026–2027e, and reiterate our BUY and NOK149 target price.

Softer operating profit, better financials

Adj PTP +5%/-2%, on better financials, but much weaker op.profit. Softer fee, insurance and opex behind the miss, financials beat. Cons.est.rev -2-4%, stock -2% to 4% on the operating profit miss

Heads-up for Q1-report, 7 May

Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highli...

Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.

Efficient execution

Q1'25: delivering on EBITA

A setback for AUM and returns

Stora Enso (Buy, TP: EUR12.00) - Reassuring Q1

After a series of negative earnings surprises, the Q1 results exceeded our expectations, mainly on progress in the key Consumer Packaging division. In addition, we found it reassuring that management reiterated that the forestry asset sale is ongoing, with completion expected before end-H1. We have made limited forecast changes, and reiterate our BUY and EUR12 target price.

All chips on Oulu II